Hummingbird Bioscience Pte. Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Nov 2038
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 27, 2026The maintenance fee for CD47 antigen-binding molecules (US 11,685,789) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
- 1 fee due Apr 10, 2027The maintenance fee for HER3 Antigen-Binding Molecules (US 11,780,933) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
- 1 fee due Jul 16, 2027The maintenance fee for Vista Antigen-Binding Molecules (US 11,873,346) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
- 1 fee due Oct 28, 2027The maintenance fee for Vista Antigen-Binding Molecules (US 10,633,456) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,685,789 | CD47 antigen-binding molecules In force · From the USPTO record | In force | From the USPTO record | |
| US 10,633,456 | Vista Antigen-Binding Molecules In force · High confidence | In force | High confidence | |
| US 10,662,241 | HER3 Antigen-Binding Molecules In force · High confidence | In force | High confidence | |
| US 11,873,346 | Vista Antigen-Binding Molecules In force · High confidence | In force | High confidence | |
| US 11,208,498 | Treatment and Prevention of Cancer Using HER3 Antigen-Binding Molecules In force · High confidence | In force | High confidence | |
| US 11,780,933 | HER3 Antigen-Binding Molecules In force · Medium confidence | In force | Medium confidence | |
| US 12,643,952 | Bcma/Taci Antigen-Binding Molecules In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending · 4 abandoned · 2 no status recorded